BRPI0410926A - análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular - Google Patents

análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular

Info

Publication number
BRPI0410926A
BRPI0410926A BRPI0410926-0A BRPI0410926A BRPI0410926A BR PI0410926 A BRPI0410926 A BR PI0410926A BR PI0410926 A BRPI0410926 A BR PI0410926A BR PI0410926 A BRPI0410926 A BR PI0410926A
Authority
BR
Brazil
Prior art keywords
oxa
agents
intraocular pressure
azaprostaglandins
analogues
Prior art date
Application number
BRPI0410926-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David W Old
Danny Thang Dinh
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0410926A publication Critical patent/BRPI0410926A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
BRPI0410926-0A 2003-06-02 2004-05-25 análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular BRPI0410926A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/453,207 US6734206B1 (en) 2003-06-02 2003-06-02 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
PCT/US2004/016516 WO2004108670A1 (en) 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
BRPI0410926A true BRPI0410926A (pt) 2006-06-27

Family

ID=32230466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410926-0A BRPI0410926A (pt) 2003-06-02 2004-05-25 análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular

Country Status (10)

Country Link
US (1) US6734206B1 (https=)
EP (1) EP1638936B1 (https=)
JP (1) JP2006526638A (https=)
AT (1) ATE496886T1 (https=)
AU (1) AU2004245492B2 (https=)
BR (1) BRPI0410926A (https=)
CA (1) CA2528010C (https=)
DE (1) DE602004031225D1 (https=)
ES (1) ES2358513T3 (https=)
WO (1) WO2004108670A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7863318B2 (en) * 2005-11-03 2011-01-04 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
AU2211700A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
GEP20043203B (en) * 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
JP4063468B2 (ja) 2000-02-22 2008-03-19 株式会社カネボウ化粧品 寒天被覆処理顔料およびメイクアップ化粧料
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
OA12533A (en) 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
JP4520738B2 (ja) * 2001-06-14 2010-08-11 アラーガン インコーポレイテッド 眼圧降下剤としての３、７、または３および７チアまたはオキサプロスタン酸誘導体
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
CN100371322C (zh) 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
EP2255829A3 (en) 2001-07-23 2012-03-28 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists

Also Published As

Publication number Publication date
US6734206B1 (en) 2004-05-11
AU2004245492B2 (en) 2010-08-19
AU2004245492A1 (en) 2004-12-16
JP2006526638A (ja) 2006-11-24
CA2528010A1 (en) 2004-12-16
DE602004031225D1 (de) 2011-03-10
WO2004108670A1 (en) 2004-12-16
EP1638936A1 (en) 2006-03-29
CA2528010C (en) 2012-01-24
ES2358513T3 (es) 2011-05-11
ATE496886T1 (de) 2011-02-15
EP1638936B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0010555A (pt) Inibidores de neuraminidases
MX9600484A (es) Anhidrato de clorhidrato de paroxetina y procedimiento para su preparacion.
BR0316753A (pt) Método de tratamento para disfunção sexual
DE69924254D1 (de) Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
BRPI0407400A (pt) derivados do ácido 10,10-dialquil prostanóico como agentes para o abaixamento de pressão intra-ocular
BRPI0410926A (pt) análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
DE60130030D1 (de) Verfahren zur behandlung von glaukom
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
BR0214529A (pt) compostos terapêuticos
CY1112146T1 (el) Βακτηριοκτονος συνθεση για αγροτικη ή κηπουρικη χρηση και μεθοδος ελεγχου ασθενειας φυτου

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.